<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02072408</url>
  </required_header>
  <id_info>
    <org_study_id>2013-10-044-002</org_study_id>
    <nct_id>NCT02072408</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kim's Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of aflibercept for treatment
      of polypoidal choroidal vasculopathy without active polyp.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">November 2, 2017</completion_date>
  <primary_completion_date type="Actual">November 2, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of best-corrected visual acuity (ETDRS letters)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>presence of subretinal hemorrhage</measure>
    <time_frame>during 1 year</time_frame>
    <description>Total number of months when subretinal hemorrhage are detected on fundus photographs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of fluid in macula evidenced by optical coherence tomography</measure>
    <time_frame>during 1 year</time_frame>
    <description>Total number of months when fluid in macula are detected on optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of indocyanine green angiography</measure>
    <time_frame>during 1 year</time_frame>
    <description>Change of indocyanine green angiography will include followings
New appearance of polypoidal structure
Any change in size of the greatest linear dimension of lesion
Any change in size and activity of branching vascular network</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of eyes which need rescue treatment (photodynamic therapy)</measure>
    <time_frame>during 1 year</time_frame>
    <description>In this study, photodynamic therapy will be performed as a rescue therapy according to the necessary criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety outcomes</measure>
    <time_frame>one year</time_frame>
    <description>frequency and severity of ocular adverse event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Polypoidal Choroidal Vasculopathy Without Active Polyp</condition>
  <arm_group>
    <arm_group_label>polypoidal choroidal vasculopathy without polyp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aflibercept</intervention_name>
    <description>Three monthly intravitreal aflibercept (2mg) injections
Five bimonthly intravitreal aflibercept (2mg) injections
Rescue treatment: Verteporfin photodynamic therapy
Loss of five ETDRS letters or one Snellen line of vision from baseline
Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection
Presence of active polyp on indocyanine green angiography</description>
    <arm_group_label>polypoidal choroidal vasculopathy without polyp</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  polypoidal choroidal vasculopathy without active polyp

          -  decreased visual acuity by subretinal fluid and hemorrhage involving foveal center

        Exclusion Criteria:

          -  polypoidal choroidal vasculopathy with active polyp

          -  previous photodynamic therapy more than three times

          -  anti-VEGF injection within one month

          -  photodynamic therapy or intraocular steroid treatment within three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyunggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konyang University Kim's Eye Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <last_update_submitted>September 2, 2018</last_update_submitted>
  <last_update_submitted_qc>September 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

